跳至主要内容
临床试验/EUCTR2004-000617-19-EE
EUCTR2004-000617-19-EE进行中(未招募)不适用

A Randomized Controlled Study of Docetaxel Monotherapy or Docetaxel and DOXIL for the Treatment of Advanced Breast Cancer - DOXIL BCA

Janssen-Cilag International N.V.0 个研究点目标入组 720 人开始时间: 2005年12月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
720

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • - Age 18 years or older
  • - Advanced breast cancer (Stage IIIb, not amenable to surgical treatment or Stage IV), for which there is histologic or cytologic proof of malignancy
  • - Presence of measurable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST) provided in Attachment 4, RECIST Criteria
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - More than 1 prior cytotoxic chemotherapy regimen for advanced breast cancer (this does not include treatment given in the neoadjuvant or adjuvant setting)
  • - Treatment of advanced breast cancer with an anthracycline, paclitaxel, docetaxel, vinorelbine, or vinblastine (prior treatment of advanced breast cancer with 1 regimen that includes alkylating agents or antimetabolite agents is acceptable)

研究者

相似试验